Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy

Japanese Journal of Radiology volume 35, pages740–747(2017)Cite this article

Abstract

Purpose

This study aimed to evaluate the predictive and prognostic value of FDG PET/CT-based volumetric parameters in patients with oral tongue squamous cell carcinoma (OTSCC) treated by superselective intra-arterial chemoradiotherapy (IA-CRT).

Methods

We conducted a retrospective study including 33 patients with biopsy-proven OTSCC between May 2007 and February 2016. All of the patients were treated by IA-CRT. Pretreatment SUVmax and metabolic tumor volume (MTV) of the primary tumor were measured. The SUV thresholds of 2.5 and 5.0 were used. Progression-free survival (PFS) and overall survival (OS) were chosen as endpoints to evaluate prognosis. Univariate and multivariate analyses were performed to assess the potential independent effect of FDG PET/CT parameters.

Results

The median follow-up for surviving patients was 40.7 months (range 6.0–107.5 months). In univariate and multivariate analyses, SUVmax and MTV (5.0) were independent prognostic factors for PFS. In univariate analysis, SUVmax failed to predict OS. MTV (5.0) was a significant prognostic factor for OS, but multivariate analysis failed to show statistical independence because it could not exclude the possibility of an artifact due to N stage.

Conclusions

FDG PET/CT-based volumetric parameters may be significant prognostic markers for survival of patients with OTSCC who are treated by IA-CRT.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I). Oral Oncol. 2010;46(9):630–5.

    Article  PubMed  Google Scholar 

  2. 2.

    Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol. 2010;46(9):636–43.

    Article  PubMed  Google Scholar 

  3. 3.

    Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917–23.

    Article  PubMed  Google Scholar 

  4. 4.

    Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607.

    Article  PubMed  Google Scholar 

  5. 5.

    Gore SM, Crombie AK, Batstone MD, Clark JR. Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck. 2015;37(4):518–23.

    Article  PubMed  Google Scholar 

  6. 6.

    Robbins KT, Kumar P, Regine WF, Wong FS, Weir AB 3rd, Flick P, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38(2):263–71.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Mitsudo K, Koizumi T, Iida M, Nakashima H, Oguri S, Kioi M, et al. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol. 2014;111(2):306–10.

    Article  PubMed  Google Scholar 

  8. 8.

    Doweck I, Robbins KT, Samant S, Vieira F. Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma. World J Surg Oncol. 2008;6:2.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Salesiotis AN, Cullen KJ, et al. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol. 2000;12:29–39.

    Article  Google Scholar 

  10. 10.

    La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1335–41.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(2):514–21.

    Article  PubMed  Google Scholar 

  12. 12.

    Shimizu M, Mitsudo K, Koike I, Taguri M, Iwai T, Koizumi T, et al. Prognostic value of 2-[(18) F]fluoro-2-deoxy-d-glucose positron emission tomography for patients with oral squamous cell carcinoma treated with retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(3):239–47.

    Article  PubMed  Google Scholar 

  13. 13.

    Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1514–20.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Hanamoto A, Tatsumi M, Takenaka Y, Hamasaki T, Yasui T, Nakahara S, et al. Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. Cancer Med. 2014;3(5):1368–76.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Yabuki K, Shiono O, Komatsu M, Sano D, Nishimura G, Takahashi M, et al. Predictive and prognostic value of metabolic tumor volume (MTV) in patients with laryngeal carcinoma treated by radiotherapy (RT)/concurrent chemoradiotherapy (CCRT). PLoS One. 2015;10(2):e0117924.

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Garsa AA, Chang AJ, Dewees T, Spencer CR, Adkins DR, Dehdashti F, et al. Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. J Radiat Oncol. 2013;2(1):27–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Lee SJ, Choi JY, Lee HJ, Baek CH, Son YI, Hyun SH, et al. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma. Korean J Radiol. 2012;13(6):752–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Abgral R, Keromnes N, Robin P, Le Roux PY, Bourhis D, Palard X, et al. Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(4):659–67.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Chung MK, Jeong HS, Son YI, So YK, Park GY, Choi JY, et al. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16(11):3111–7.

    Article  PubMed  Google Scholar 

  21. 21.

    Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys. 2012;83(5):1521–7.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Kanagawa Cancer Center Collaborative Project between Hospital and Research Institute.

Author information

Affiliations

  1. Department of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Satoko Suzuki-Shibata, Yayoi Yamamoto & Tetsuo Yoshida

  2. Department of Radiation Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Nobutaka Mizoguchi & Tetsuo Nonaka

  3. Department of Head and Neck Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Akira Kubota

  4. Cancer Preservation and Control Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Hiroto Narimatsu

  5. Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Yohei Miyagi

  6. Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan

    Toshiaki Kobayashi

  7. Department of Radiology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan

    Tomohiro Kaneta & Tomio Inoue

Authors
  1. Satoko Suzuki-Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yayoi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobutaka Mizoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuo Nonaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroto Narimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yohei Miyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshiaki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomohiro Kaneta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tomio Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoko Suzuki-Shibata.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Suzuki-Shibata, S., Yamamoto, Y., Yoshida, T. et al. Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy. Jpn J Radiol 35, 740–747 (2017). https://doi.org/10.1007/s11604-017-0686-z

Download citation

Keywords

  • Oral tongue squamous cell carcinoma
  • Metabolic tumor volume
  • FDG PET/CT